For example, autologous CD4+ T cells from AD cases could be captured with HLA specific tau tetramers, expanded and skewed towards a regulatory phenotype in-vitro and re-administered to patients, a therapeutic strategy which is being explored in the context of different antigens in type 1 diabetes,97 PD98 and MS.99 Equally, as our understanding of how HLA-I is involved in axonal development and pruning improves, avenues to therapeutically target this pathway could reveal themselves. The gene discussed is CD4; the disease is Alzheimer disease.